Related Experiment Video
Updated: Nov 29, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Endogenous retroviruses expressed in human tumours cannot be used as targets for anti-tumour vaccines
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany.
Abstract:
Many tumour cells express on their surface proteins of endogenous retroviruses (ERVs) and there are suggestions to use these retroviral antigens as target for anti-tumour vaccines. However, until now there is no convincing data showing that this strategy works, in contrast, there are considerations suggesting that this strategy may be harmful if applied.
Insights
Many tumor cells express endogenous retroviral (ERV) proteins, suggesting their use in anti-tumor vaccines. However, current evidence lacks convincing proof of efficacy and raises concerns about potential harm from this strategy.
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- Tumor cells often express proteins from endogenous retroviruses (ERVs) on their surface.
- These ERV proteins are considered potential targets for anti-tumor vaccines.
Purpose of the Study:
- To evaluate the efficacy of targeting endogenous retroviral antigens for anti-tumor vaccines.
- To assess potential risks associated with using ERV-based anti-tumor immunotherapy.
Main Methods:
- Review of existing data and literature on endogenous retroviruses and cancer immunotherapy.
- Analysis of theoretical considerations regarding the immune response to ERV antigens in cancer patients.
Main Results:
- Lack of convincing evidence supporting the efficacy of ERV-targeted anti-tumor vaccines.
- Emerging concerns and theoretical considerations suggest this strategy may be detrimental.
Conclusions:
- The therapeutic application of targeting endogenous retroviral antigens in cancer vaccines is not supported by current evidence.
- Further research is needed to clarify the potential benefits and risks before clinical application.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
19:02High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Retroviruses
Tumor Immunotherapy
Retrovirus Life Cycles